Skip to main content
. 2024 Mar 12;13(1):21. doi: 10.3390/antib13010021

Table 1.

Comparison between new 2023 ACR/EULAR APS classification criteria and 2006 revised Sapporo classification criteria.

2006 Revised Sapporo 2023 ACR/EULAR
Classification ≥1 clinical criteria
AND
≥1 laboratory criteria		 ≥3 points from clinical domains
AND
≥3 points from laboratory domains
Clinical criteria Clinical criteria:
1. Vascular thrombosis: ≥1 clinical episode of arterial, venous, or microvascular thrombosis in any tissue or organ
2. Pregnancy morbidity		 Clinical domains:
1. Macrovascular—venous thromboembolism *
2. Macrovascular—arterial thromboembolism *
3. Microvascular **
4. Obstetric
5. Cardiac valve
6. Hematology
Included in the APS criteria

  • Heart valve disease

 No Yes

  • Livedo racemosa

 No Yes

  • Thrombocytopenia

 No Yes

  • Nephropathy

 No Yes

  • Neurological manifestations

 No No

  • Pulmonary hemorrhage

 No Yes

  • Adrenal hemorrhage

 No Yes
Laboratory criteria
Persistent positivity (at 12 weeks) Yes Yes
Timeline of aPL positivity and clinical criteria Within 5 years of clinical criterion Within 3 years of clinical criterion
Threshold of aCL and/or aβ2GP1 aCL > 40 GPL/MPL units, or >99th percentile
aβ2GP1 > 99th percentile		 aCL or aβ2GP1:
Moderate: 40–79 units
High: ≥80 units
Antibodies for laboratory criteria

  • Positive LAC

 Yes Yes

  • IgG aCL or aβ2GP1

 Yes Yes

  • IgM and/or aβ2GP1

 Yes Yes (not sufficient if isolated)

* in the setting of high- or low-thrombotic risk profiles (diagnostic weight varying). ** proven histologically or clinically (diagnostic weight varying). aPL: antiphospholipid antibodies, aCL: anticardiolipin antibodies, aβ2GP1: anti-beta-2 glycoprotein 1 antibodies, GPL: IgG phospholipid unit, MPL: IgM phospholipid unit, LAC: lupus anticoagulant. Adapted from [9].